Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07233239 | A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures | PHASE1 | RECRUITING | 100 | — | — | Nov 26, 2025 | Nov 29, 2027 | Jun 3, 2026 | 24 | United States |
| Arm | Type | Description |
|---|---|---|
| CBD-OS | EXPERIMENTAL | Participants who will receive open-label CBD-OS. |
| Name | Type | Description |
|---|---|---|
| CBD-OS | DRUG | Starting dose of CBD-OS will be administered as per the approved local product label |
Participants are eligible to be included in the main study only if all of the following criteria apply: 1. Participant has a documented diagnosis of focal epilepsy according to the ILAE Classification of Epilepsy, 2017, characterized by focal seizure types with typical interictal/ictal EEG findings...